7 April 2026 - PHARMAC will widen access to two melanoma medicines, giving New Zealanders another funded immunotherapy option and reducing the amount of treatment some people may need.

From 1 May 2026, people with stage 3B to stage 4 melanoma that can be removed with surgery will be eligible for funded nivolumab and ipilimumab before surgery.

Read PHARMAC press release